Compare Stocks: SPHRY, OLMA, DBVT, and ACRS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACRS Aclaris Therapeutics	$6.28 -3.9%	$5.55	$1.74 ▼ $6.60	$879.33M	0.78	1.93 million shs	434,707 shs
DBVT DBV Technologies	$14.35 -4.1%	$14.91	$8.70 ▼ $26.18	$902.33M	-0.93	298,932 shs	68,402 shs
OLMA Olema Pharmaceuticals	$10.79 -1.1%	$11.38	$5.36 ▼ $36.26	$943.43M	2.03	1.41 million shs	72,794 shs
SPHRY Starpharma	$5.03	$4.88	$0.73 ▼ $5.70	$239.72M	1.25	480 shs	100 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACRS Aclaris Therapeutics	+3.49%	+3.65%	+24.86%	+42.58%	+262.78%
DBVT DBV Technologies	+5.87%	+3.46%	+9.83%	-19.08%	+52.91%
OLMA Olema Pharmaceuticals	+4.60%	+2.44%	-6.75%	-15.49%	+95.17%
SPHRY Starpharma	+3.40%	-3.37%	+8.86%	+5.61%	+442.60%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACRS Aclaris Therapeutics	$6.28 -3.9%	$5.55	$1.74 ▼ $6.60	$879.33M	0.78	1.93 million shs	434,707 shs
DBVT DBV Technologies	$14.35 -4.1%	$14.91	$8.70 ▼ $26.18	$902.33M	-0.93	298,932 shs	68,402 shs
OLMA Olema Pharmaceuticals	$10.79 -1.1%	$11.38	$5.36 ▼ $36.26	$943.43M	2.03	1.41 million shs	72,794 shs
SPHRY Starpharma	$5.03	$4.88	$0.73 ▼ $5.70	$239.72M	1.25	480 shs	100 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACRS Aclaris Therapeutics	+3.49%	+3.65%	+24.86%	+42.58%	+262.78%
DBVT DBV Technologies	+5.87%	+3.46%	+9.83%	-19.08%	+52.91%
OLMA Olema Pharmaceuticals	+4.60%	+2.44%	-6.75%	-15.49%	+95.17%
SPHRY Starpharma	+3.40%	-3.37%	+8.86%	+5.61%	+442.60%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACRS Aclaris Therapeutics	3.13	Buy	$11.50	83.24% Upside
DBVT DBV Technologies	2.71	Moderate Buy	$48.50	237.98% Upside
OLMA Olema Pharmaceuticals	2.71	Moderate Buy	$42.40	292.96% Upside
SPHRY Starpharma	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest SPHRY, OLMA, DBVT, and ACRS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/17/2026	OLMA Olema Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/13/2026	OLMA Olema Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$52.00 ➝ $46.00
8/11/2026	OLMA Olema Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$38.00 ➝ $36.00
8/11/2026	OLMA Olema Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$59.00
8/3/2026	OLMA Olema Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/17/2026	DBVT DBV Technologies	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/17/2026	OLMA Olema Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/30/2026	DBVT DBV Technologies	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
6/30/2026	DBVT DBV Technologies	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Market Outperform	$47.00 ➝ $55.00
6/29/2026	DBVT DBV Technologies	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/24/2026	ACRS Aclaris Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 8/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACRS Aclaris Therapeutics	$7.83M	112.07	N/A	N/A	$0.89 per share	7.05
DBVT DBV Technologies	$5.64M	159.99	N/A	N/A	$2.55 per share	5.63
OLMA Olema Pharmaceuticals	N/A	N/A	N/A	N/A	$4.92 per share	N/A
SPHRY Starpharma	$3.18M	75.38	N/A	N/A	$0.29 per share	17.33

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACRS Aclaris Therapeutics	-$64.92M	-$0.58	N/A	N/A	N/A	-921.50%	-61.65%	-42.41%	11/5/2026 (Estimated)
DBVT DBV Technologies	-$146.95M	-$3.51	N/A	N/A	N/A	-3,506.53%	-119.33%	-84.43%	10/28/2026 (Estimated)
OLMA Olema Pharmaceuticals	-$162.45M	-$2.12	N/A	N/A	N/A	N/A	-48.26%	-43.04%	11/9/2026 (Estimated)
SPHRY Starpharma	-$6.47M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	8/26/2026 (Estimated)

Latest SPHRY, OLMA, DBVT, and ACRS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/10/2026	Q2 2026	OLMA Olema Pharmaceuticals	-$0.5515	-$0.61	-$0.0585	-$0.61	N/A	N/A
8/6/2026	Q2 2026	ACRS Aclaris Therapeutics	-$0.16	-$0.15	+$0.01	-$0.15	$1.38 million	$1.63 million
7/16/2026	Q2 2026	DBVT DBV Technologies	-$0.12	-$0.60	-$0.48	-$0.60	$0.90 million	$0.70 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACRS Aclaris Therapeutics	N/A	N/A	N/A	N/A	N/A
DBVT DBV Technologies	N/A	N/A	N/A	N/A	N/A
OLMA Olema Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SPHRY Starpharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACRS Aclaris Therapeutics	N/A	3.46	3.46
DBVT DBV Technologies	N/A	3.72	3.72
OLMA Olema Pharmaceuticals	0.01	8.86	8.86
SPHRY Starpharma	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACRS Aclaris Therapeutics	98.34%
DBVT DBV Technologies	71.74%
OLMA Olema Pharmaceuticals	91.78%
SPHRY Starpharma	N/A

Insider Ownership

Company	Insider Ownership
ACRS Aclaris Therapeutics	4.80%
DBVT DBV Technologies	1.06%
OLMA Olema Pharmaceuticals	12.56%
SPHRY Starpharma	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACRS Aclaris Therapeutics	100	139.82 million	133.11 million	Optionable
DBVT DBV Technologies	80	62.88 million	62.21 million	Optionable
OLMA Olema Pharmaceuticals	70	87.50 million	76.51 million	Optionable
SPHRY Starpharma	45	47.71 million	N/A	Not Optionable

SPHRY, OLMA, DBVT, and ACRS Headlines

Recent News About These Companies

Starpharma Holdings Ltd ADR SPHRY

May 7, 2026 | morningstar.comM

Starpharma enters collaboration, license agreement with Genentech

September 22, 2025 | msn.com

Starpharma Announces a Collaboration and License Agreement with Genentech

September 22, 2025 | markets.businessinsider.com

SPHRY Starpharma Holdings Limited

June 19, 2025 | seekingalpha.com

Change in Substantial Holder’s Voting Power at Starpharma Holdings

June 3, 2025 | tipranks.com

Pleasing Signs As A Number Of Insiders Buy Starpharma Holdings Stock

May 5, 2025 | uk.finance.yahoo.com

Starpharma Advances Strategic Initiatives and Expands Market Presence

April 29, 2025 | tipranks.com

Is Starpharma Holdings (ASX:SPL) In A Good Position To Deliver On Growth Plans?

March 25, 2025 | finance.yahoo.com

Robmar Investments Acquires Substantial Stake in Starpharma Holdings

March 17, 2025 | tipranks.com

Starpharma Highlights DEP® Dendrimer Platform at PepTalk Conference

January 15, 2025 | tipranks.com

Astodrimer by Starpharma for Coronavirus Disease 2019 (COVID-19): Likelihood of Approval

December 30, 2024 | pharmaceutical-technology.comP

Starpharma CEO Receives Major Performance Rights Issuance

December 12, 2024 | markets.businessinsider.com

Starpharma Issues Unquoted Securities to Boost Employee Incentives

December 12, 2024 | markets.businessinsider.com

Starpharma Holdings Reports Successful AGM Results

November 29, 2024 | tipranks.com

Starpharma Holdings Schedules Reconvened AGM for Key Vote

November 26, 2024 | tipranks.com

Starpharma AGM Results Highlight Voting Challenges

November 26, 2024 | tipranks.com

Starpharma Holdings Highlights Strategic Advances in 2024

November 25, 2024 | tipranks.com

Starpharma Highlights Dendrimer Technology at Healthcare Conference

November 18, 2024 | markets.businessinsider.com

Starpharma Showcases Dendrimer Innovations at Microcap Conference

October 29, 2024 | markets.businessinsider.com

Medicxi, Starpharma create Petalion with $25M round

April 9, 2024 | bioworld.comB

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPHRY, OLMA, DBVT, and ACRS Company Descriptions

Aclaris Therapeutics NASDAQ:ACRS

$6.28 -0.25 (-3.89%)

As of 10:58 AM Eastern

Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

DBV Technologies NASDAQ:DBVT

$14.35 -0.62 (-4.14%)

As of 10:56 AM Eastern

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

Olema Pharmaceuticals NASDAQ:OLMA

$10.79 -0.12 (-1.10%)

As of 10:58 AM Eastern

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

Starpharma OTCMKTS:SPHRY

$5.03 0.00 (0.00%)

As of 08/25/2026 09:40 AM Eastern

Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis and prevention of recurrent BV; VIRALEZE, an antiviral nasal spray; and VivaGel condom, an antiviral condom. It is also involved in the development of DEP cabazitaxel that is in Phase 2 clinical trial for the treatment of prostate and other cancers, DEP docetaxel that is in Phase 2 clinical trials for the treatment of colorectal and other cancers, DEP irinotecan that is in Phase 2 clinical trials f for the treatment of pancreatic and other cancers; and EP gemcitabine, DEP HER-2 ADC, and DEP HER-2 radiotherapy completed preclinical trials for the treatment of solid cancers. In addition, the company's DEP radiotheranostics development pipeline includes DEP HER2-zirconium, a HER2-targeted radio diagnostic for HER2-positive cancers, such as breast and gastric cancer; and HER2-targeted DEP SN38 ADC, a targeted ADC therapeutic for the treatment of human ovarian cancer. Starpharma Holdings Limited was incorporated in 1997 and is headquartered in Abbotsford, Australia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SPHRY, OLMA, DBVT, and ACRS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SPHRY, OLMA, DBVT, and ACRS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SPHRY, OLMA, DBVT, and ACRS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPHRY, OLMA, DBVT, and ACRS Company Descriptions

Aclaris Therapeutics NASDAQ:ACRS

DBV Technologies NASDAQ:DBVT

Olema Pharmaceuticals NASDAQ:OLMA

Starpharma OTCMKTS:SPHRY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SPHRY, OLMA, DBVT, and ACRS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SPHRY, OLMA, DBVT, and ACRS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SPHRY, OLMA, DBVT, and ACRS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPHRY, OLMA, DBVT, and ACRS Company Descriptions

Aclaris Therapeutics NASDAQ:ACRS

DBV Technologies NASDAQ:DBVT

Olema Pharmaceuticals NASDAQ:OLMA

Starpharma OTCMKTS:SPHRY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools